Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 7/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | TP53 | P04637 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALPG | P10696 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17830719 | 0.88 | MAPT (0.61) | POLBSMN1; SMN2MAPTTP53KMT2A | |
| SCHEMBL16366691 | 0.85 | POLB (0.58) | POLBSMN1; SMN2MAPTTP53KMT2A | |
| SCHEMBL16366688 | 0.84 | POLB (0.58) | POLBSMN1; SMN2MAPTTP53KMT2A | |
| SCHEMBL16366690 | 0.83 | POLB (0.56) | POLBSMN1; SMN2MAPTTP53KMT2A | |
| SCHEMBL4420231 | 0.79 | LMNA (0.70) | POLBSMN1; SMN2MAPTTP53KMT2A | |
| SCHEMBL16366689 | 0.79 | POLB (0.60) | POLBSMN1; SMN2MAPTTP53KMT2A | |
| SCHEMBL4411764 | 0.78 | TP53 (0.61) | POLBMAPTTP53KMT2AMEN1 | |
| SCHEMBL16366687 | 0.78 | POLB (0.59) | POLBSMN1; SMN2MAPTTP53KMT2A | |
| SCHEMBL4414360 | 0.77 | HPGD (0.64) | POLBMAPTTP53KMT2AMEN1 | |
| SCHEMBL16366686 | 0.76 | POLB (0.55) | POLBSMN1; SMN2MAPTTP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | POLB 2366/4885SMN1; SMN2 4357/4885MAPT 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.